Apollo Medical Holdings Reports 46% Revenue Growth Year Over Year For The 1st Quarter Of 2018

PR Newswire

ALHAMBRA, Calif. and GLENDALE, Calif., May 15, 2018 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed" or "the Company") (NASDAQ: AMEH), an integrated population health management company, today announced its consolidated 1st Quarter financial results for the three months ended March 31, 2018.

Financial Highlights for the Three Months Ended March 31, 2018 Compared to the Three Months Ended March 31, 2017 (unaudited):

  • Net revenue of $124.2 million as compared to net revenue of $85.3 million in the comparable period of 2017, an increase of 46%.
  • Income from operations of $22.7 million as compared to $15.7 million in the comparable period of 2017, an increase of 45%.
  • Net income attributable to Apollo Medical Holdings, Inc. of $2.2 million as compared to $4.3 million in the comparable period of 2017, a decrease of 50%. The decrease in net income was due to post-merger integration-related costs and investments to support two new management services agreements ("MSA"). The Company expects to substantially complete its merger integration by the end of Q2 and does not expect any further material expenditures to support the new contracts beyond Q1.
  • As of March 31, 2018, the Company had total assets of $521.6 million, including cash and cash equivalents of $103.7 million.

Notes to the Financial Highlights for the Three Months Ended March 31, 2018:

  • On January 8, 2018, the Company announced that it had entered into a ten year MSA with Accountable Health Care IPA to manage 160,000 capitated health plan members, including all hospital risk pools.
  • On February 5, 2018, the Company announced that it had entered into an MSA with Golden Shore Medical Group to manage over 100,000 capitated health plan members in four California counties. Dr. J. Mario Molina, formerly the Chief Executive Officer and Chairman of Molina Healthcare, serves as President and owner of Golden Shore.

"We are very pleased with the progress of our long term growth initiatives, especially with our continued strong organic revenue growth," stated Warren Hosseinion, M.D., Co-Chief Executive Officer of Apollo Medical Holdings.  "We are confident in our future and believe we are well-positioned for continued growth."

"In Q1 2018, our management team focused on integrating the two companies post-merger," stated Thomas Lam, M.D., Co-Chief Executive Officer of Apollo Medical Holdings.  "We also made important investments to support the management of the additional 260,000 patients."

"We are pleased with our Q1 2018 financial results," stated Kenneth Sim, M.D., Executive Chairman of Apollo Medical Holdings. "We believe that there will be no further material investments necessary to support the new contracts in Q2 and expect that post-merger integration costs will be less in Q2 than in Q1 and the integration will be substantially completed by the end of Q2. We look forward to the rest of fiscal year 2018."

For more details on ApolloMed's March 31, 2018 quarter end results, please refer to the Company's Quarterly Report on Form 10-Q filed with the U.S. Securities Exchange Commission and accessible at www.sec.gov.  

APOLLO MEDICAL HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)



March 31,
2018



December 31,
2017









Assets


















Current assets









Cash and cash equivalents


$

103,731,761



$

99,749,199


Restricted cash – short-term



18,028,116




18,005,661


Fiduciary cash



1,386,474




2,017,437


Investment in marketable securities



1,138,477




1,143,095


Receivables, net



52,805,123




20,117,304


Prepaid expenses and other current assets



3,525,437




3,126,866











Total current assets



180,615,388




144,159,562











Noncurrent assets









Land, property and equipment, net



13,700,034




13,814,306


Intangible assets, net



99,138,657




103,533,558


Goodwill



188,933,191




189,847,202


Loans receivable – related parties



5,000,000




5,000,000


Loan receivable



10,000,000




10,000,000


Investments in other entities – equity method



21,875,500




21,903,524


Restricted cash – long-term



745,293




745,235


Other assets



1,585,850




1,632,406











Total noncurrent assets



340,978,525




346,476,231











Total assets


$

521,593,913



$

490,635,793









Liabilities, Mezzanine Equity and Stockholders' Equity


















Current liabilities









Lines of credit


$

5,000,000



$

5,025,000


Accounts payable and accrued expenses



12,110,530




13,279,620


Incentives payable



14,900,000




21,500,000


Fiduciary accounts payable



1,386,474




2,017,437


Medical liabilities



69,110,826




63,972,318


Income taxes payable



7,614,669




3,198,495


Bank loan, short-term



394,783




510,391


Capital lease obligations



99,480




98,738











Total current liabilities



110,616,762




109,601,999











Noncurrent liabilities









Deferred tax liability



30,055,819




24,916,598


Liability for unissued equity shares



1,185,025




1,185,025


Dividend payable



18,000,000




18,000,000


Capital lease obligations, net of current portion



593,852




619,001











Total noncurrent liabilities



49,834,696




44,720,624











Total liabilities



160,451,458




154,322,623











Commitments and Contingencies


















Mezzanine equity









Noncontrolling interest in Allied Pacific of California IPA ("APC")



190,654,312




172,129,744











Stockholders' equity









Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and zero outstanding



-




-


Series B Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series A Preferred stock); 555,555 issued and zero outstanding



-




-


Common stock, par value $0.001; 100,000,000 shares authorized, 32,652,295 and 32,304,876 shares outstanding, excluding 1,682,110 shares held by APC, at March 31, 2018 and December 31, 2017, respectively



32,653




32,305


Additional paid-in capital



160,736,190




158,181,192


Retained earnings



4,897,454




1,734,531





165,666,297




159,948,028











Noncontrolling interest



4,821,846




4,235,398











Total stockholders' equity



170,488,143




164,183,426











Total liabilities, mezzanine equity and stockholders' equity


$

521,593,913



$

490,635,793


 

APOLLO MEDICAL HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended March 31,


2018



2017









Revenue









Capitation, net


$

85,905,284



$

64,716,133


Risk pool settlements and incentives



17,986,736




11,137,200


Management fee income



12,074,572




6,537,110


Fee-for-service, net



7,748,109




2,663,913


Other income



452,026




281,706











Total revenue



124,166,727




85,336,062











Expenses









Cost of services



84,670,608




59,607,514


General and administrative expenses



11,735,898




5,211,633


Depreciation and amortization



5,058,512




4,836,351











Total expenses



101,465,018




69,655,498











Income from operations



22,701,709




15,680,564











Other income (expense)









(Loss) income from equity method investments



(28,024)




2,227,262


Interest expense



(85,001)




(811)


Interest income



269,818




182,285


Change in fair value of derivative instrument



-




1,522,222


Other income



87,993




1,514











Total other income, net



244,786




3,932,472











Income before provision for income taxes



22,946,495




19,613,036











Provision for income taxes



7,228,840




7,889,245











Net income



15,717,655




11,723,791











Net income attributable to noncontrolling interests



13,557,200




7,374,130











Net income attributable to Apollo Medical Holdings, Inc.


$

2,160,455



$

4,349,661











Earnings per share – basic


$

0.07



$

0.17











Earnings per share – diluted


$

0.06



$

0.15











Weighted average shares of common stock outstanding – basic



32,421,467




25,067,954











Weighted average shares of common stock outstanding – diluted



38,098,373




28,445,647











Note About Historical Results for Periods Prior to the Merger

Following the closing of the merger involving Apollo Medical Holdings, Inc. ("ApolloMed") and Network Medical Management, Inc. ("NMM") in December 2017 (the "Merger"), NMM is now a wholly-owned subsidiary of ApolloMed and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed. For accounting purposes, the Merger is treated as a "reverse acquisition" and NMM is considered the accounting acquirer and ApolloMed the accounting acquiree. Accordingly, as of the closing of the Merger, for comparison purposes, NMM's historical results of operations replaced ApolloMed's historical results of operations for all periods prior to the Merger, and the results of operations of both companies are included in the Company's consolidated financial statements for all periods following the Merger.

Note About Consolidated Entities

The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities ("VIEs") in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including certain VIEs) in the Company's consolidated entities. The amount of net income attributable to noncontrolling interests is disclosed in the condensed consolidated statements of income.

Note About Stockholders' Equity, Certain Treasury Stock and Earnings Per Share

As of the date of this press release, 1,000,970 shares of ApolloMed's common stock to be issued as part of the Merger are subject to ApolloMed receiving from those former NMM shareholders a properly completed letter of transmittal (and related exhibits) before such former NMM shareholders may receive their pro rata portion of ApolloMed common stock and warrants.  Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger.  The Company's condensed consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares as of the closing of the Merger.

Shares of ApolloMed's common stock owned by Allied Physicians of California IPA (d.b.a. Allied Pacific of California IPA), a variable interest entity of the Company, are legally issued and outstanding but excluded from shares of common stock outstanding in the Company's condensed consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. Such shares, therefore, are not included in the number of shares of common stock outstanding used to calculate the Company's earnings per share.

About Apollo Medical Holdings, Inc. (ApolloMed)

ApolloMed is a leading physician-centric integrated population health management company, which, together with its subsidiaries, including a Next Generation Accountable Care Organization ("NGACO"), and its affiliated Independent Physician Associations (each, an "IPA"), are working to provide coordinated, outcomes-based high-quality medical care for patients, particularly senior patients and patients with multiple chronic conditions, in a cost-effective manner.  Led by a management team with over two decades of experience,  ApolloMed is addressing the healthcare needs of its patients by leveraging its integrated health management and healthcare delivery platform that includes: Network Medical Management (MSO),  Apollo Medical Management (MSO), ApolloMed Hospitalists, APA ACO (Next Generation ACO), Allied Physicians of California (IPA), Maverick Medical Group (IPA) and Apollo Care Connect (Digital Population Health Management Platform). ApolloMed strives to improve medical outcomes with high-quality, cost-efficient care.  For more information, please visit www.apollomed.net.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company's integration-related costs following the closing of the Merger, the expected substantial completion of such integration, the future growth of the Company, the Company's future business model, financial conditions and strategic transactions (including mergers, acquisitions and management services agreements) as well as the prospects of and future investments for the Company's strategic transactions. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, associated with such statements, many of which are beyond the control of the Company, which could cause the actual results, performance or achievements of the Company and its subsidiaries and variable interest entities to be materially different than those that may be anticipated on the basis of historical trends. Examples of such risks and uncertainties include but are not limited to:

  • risks related to the Company's ability, following the consummation of the reverse merger of Apollo Medical Holdings, Inc. and Network Medical Management, Inc., to successfully integrate operations of the two groups, including realizing the synergies anticipated from the transaction, which may not be fully realized or may take longer to realize than expected; and the Company's ability to successfully locate new strategic targets and integrate its operations following mergers, acquisitions or other strategic transactions, including that the integration may be more costly or more time consuming and complex than anticipated and that synergies anticipated to be realized may not be fully realized or may take longer to realize than expected,
  • the Company's dependence on a few key payors,
  • the impact of emerging and existing competitors, the effect of new legislation on the Company's industry and business,
  • the effectiveness of the Company's compliance and control initiatives,
  • the success of the Company's focus on next generation accountable care organization ("NGACO"), including whether the Company can continue to participate in the All-Inclusive Population-Based Payment ("AIPBP") Mechanism of the NGACO Model,
  • the possibility that the Company's expenses may exceed capitation payments, whether from CMS under the AIPBP Mechanism or health plans, which could lead to substantial losses, including that the final settlements of such incurred expenses and the Company's actual earnings or losses are generally determined in subsequent periods,
  • general economic uncertainty, and
  • other factors described from time to time in the Company's reports to the U.S. Securities and Exchange Commission (including without limitation the "Risk Factors" discussed in the Company's Annual Report on Form 10-K filed on April 2, 2018).

Should one or more of these risks or uncertainties materialize, or should any expectations or assumptions underlying the relevant forward-looking statements prove incorrect, the Company's actual results, performance or achievements may vary materially from those described in such statements as being expected, anticipated, intended, planned, believed, sought, estimated or projected. Investors and other readers, therefore, should not place reliance on any forward-looking statements or use any historical trends to anticipate or predicate results or trends in future periods. Any statements included herein are made only as of the date hereof. The Company undertakes no obligation to update or revise any statement to reflect the impact of circumstances or events that arise after the date hereof, except as required by law, and also undertakes no obligation to correct or update information prepared by third parties.

FOR MORE INFORMATION, PLEASE CONTACT:

Warren Hosseinion, M.D.
Co-Chief Executive Officer
Apollo Medical Holdings, Inc.
(818) 839-5200
warrenhoss@apollomed.net                                                                     

 

Cision View original content:http://www.prnewswire.com/news-releases/apollo-medical-holdings-reports-46-revenue-growth-year-over-year-for-the-1st-quarter-of-2018-300649100.html

SOURCE Apollo Medical Holdings, Inc.